Production (Stage)
Crinetics Pharmaceuticals, Inc.
CRNX
$31.77
-$0.40-1.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.07% | -4.90% | -3.74% | -10.65% | -11.37% |
| Total Depreciation and Amortization | 17.39% | 2.34% | 2.26% | 58.86% | 80.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.67% | 0.35% | -5.50% | 49.27% | -16.21% |
| Change in Net Operating Assets | -2,996.43% | 85.69% | -118.87% | 323.59% | -67.57% |
| Cash from Operations | -36.77% | -2.95% | -37.72% | 13.70% | -37.23% |
| Capital Expenditure | -20.41% | -94.89% | 44.71% | 28.30% | -42.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 84.34% | -2,660.50% | 140.11% | -3,310.60% | 101.90% |
| Cash from Investing | 84.14% | -2,731.11% | 138.41% | -17,459.55% | 100.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.24% | 896.38% | 973.17% | -98.67% | 957.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -2,037.10% | -10,842.86% | 100.08% | -1,750.27% |
| Cash from Financing | -99.20% | 866.45% | 943.07% | -98.60% | 937.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -222.39% | -449.00% | 116.11% | -127.49% | 487.98% |